Log in

Relevant bibliographies by topics / Dual Anti-Platelet Therapy

Academic literature on the topic 'Dual Anti-Platelet Therapy'

Author: Grafiati

Published: 10 December 2022

Last updated: 29 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Journal articles
Book chapters

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Dual Anti-Platelet Therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Dual Anti-Platelet Therapy"

1

Webster, Tyler D., Prashant Vaishnava, and Kim A. Eagle. "Perioperative management of dual anti-platelet therapy." Hospital Practice 44, no. 5 (October 19, 2016): 237–41. http://dx.doi.org/10.1080/21548331.2016.1260997.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Segal, Jonathan, and Guven Kaya. "Dual Anti-Platelet Therapy and Gastrointestinal Protection Audit." American Journal of Gastroenterology 107 (October 2012): S116. http://dx.doi.org/10.14309/00000434-201210001-00269.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Cutlip, Donald E. "Dual Anti-platelet Therapy after Coronary Stenting: Rationale for Personalized Duration of Therapy." US Cardiology Review 11, no. 1 (2017): 31. http://dx.doi.org/10.15420/usc.2017:7:2.

Full text

Abstract:

There is controversy regarding the appropriate duration of dual anti-platelet therapy after coronary stenting. Recent guidance has been updated to reflect improved outcomes after second-generation drug-eluting stenting, but a standard duration for all patients is not rational given the different risks for ischemic and bleeding complications. This paper reviews the data for short- and long-term dual anti-platelet therapy and considers approaches for developing a personalized strategy.

APA, Harvard, Vancouver, ISO, and other styles

4

Abuzaid, Ahmed, Pragya Ranjan, Carly Fabrizio, Kevin Felpel, Raveen Chawla, Adrienne Topic, and Islam Y. Elgendy. "Single Anti-Platelet Therapy versus Dual Anti-Platelet Therapy after Transcatheter Aortic Valve Replacement: A Meta-Analysis." Structural Heart 2, no. 5 (August 1, 2018): 408–18. http://dx.doi.org/10.1080/24748706.2018.1491082.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Diener, Hans-Christoph. "Update on clopidogrel and dual anti-platelet therapy: neurology." European Heart Journal Supplements 8, suppl_G (October 1, 2006): G15—G19. http://dx.doi.org/10.1093/eurheartj/sul049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Mărginean, Alina, Claudia Bănescu, Alina Scridon, and Minodora Dobreanu. "Anti-platelet Therapy Resistance – Concept, Mechanisms and Platelet Function Tests in Intensive Care Facilities." Journal of Critical Care Medicine 2, no. 1 (January 1, 2016): 6–15. http://dx.doi.org/10.1515/jccm-2015-0021.

Full text

Abstract:

AbstractIt is well known that critically ill patients require special attention and additional consideration during their treatment and management. The multiple systems and organ dysfunctions, typical of the critical patient, often results in different patterns of enteral absorption in these patients. Anti-platelet drugs are the cornerstone in treating patients with coronary and cerebrovascular disease. Dual anti-platelet therapy with aspirin and clopidogrel is the treatment of choice in patients undergoing elective percutaneous coronary interventions and is still widely used in patients with acute coronary syndromes. However, despite the use of dual anti-platelet therapy, some patients continue to experience cardiovascular ischemic events. Recurrence of ischemic events is partly attributed to the fact that some patients have poor inhibition of platelet reactivity despite treatment. These patients are considered low- or nonresponders to therapy. The underlying mechanisms leading to resistance are not yet fully elucidated and are probably multifactorial, cellular, genetic and clinical factors being implicated. Several methods have been developed to asses platelet function and can be used to identify patients with persistent platelet reactivity, which have an increased risk of thrombosis. In this paper, the concept of anti-platelet therapy resistance, the underlying mechanisms and the methods used to identify patients with low responsiveness to anti-platelet therapy will be highlighted with a focus on aspirin and clopidogrel therapy and addressing especially critically ill patients.

APA, Harvard, Vancouver, ISO, and other styles

7

Warner, Timothy D., Sven Nylander, and Carl Whatling. "Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy." British Journal of Clinical Pharmacology 72, no. 4 (September 9, 2011): 619–33. http://dx.doi.org/10.1111/j.1365-2125.2011.03943.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Feitosa, Mateus Paiva Marques, Carla David Soffiatti, Jaime Paula Pessoa Linhares Filho, Daniel Valente Batista, Heraldo Guedis Lobo Filho, Eduardo Gomes Lima, and Carlos Vicente Serrano Júnior. "Dual platelet antiaggregation therapy after myocardial revascularization surgery." Revista da Associação Médica Brasileira 65, no. 3 (March 2019): 316–18. http://dx.doi.org/10.1590/1806-9282.65.3.316.

Full text

Abstract:

SUMMARY Coronary artery bypass graft (CABG) is a consolidated treatment in patients with coronary artery disease (CAD) for both symptom control and improvement of prognosis. The patency of venous grafts is still the most vulnerable point of the surgical treatment since it presents a high prevalence of occlusion both in the immediate postoperative period and in the long-term follow-up. Aspirin plays a well-established role in this setting, and for a long time, clopidogrel use has been restricted to patients allergic to aspirin. Recently, subgroup analyses of studies with different anti-platelet therapies have shown reduced mortality and cardiovascular events in patients on dual anti-platelet antiplatelet therapy (DAPT) undergoing CABG, although such studies have not been designed to evaluate this patient profile. However, there is still an insufficient number of randomized studies using DAPT in this context, resulting in a disagreement between the European and American cardiology societies guidelines regarding their indication and generating doubts in clinical practice.

APA, Harvard, Vancouver, ISO, and other styles

9

Henriksen, P. A., K. Palmer, and N. A. Boon. "Management of upper gastrointestinal haemorrhage complicating dual anti-platelet therapy." QJM 101, no. 4 (February 12, 2008): 261–67. http://dx.doi.org/10.1093/qjmed/hcm148.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lee, Dong Hyun, Moo Hyun Kim, Long Zhe Guo, Cai De Jin, Young Rak Cho, Kyungil Park, Jong Sung Park, Tae-Ho Park, and Victor Serebruany. "Concomitant nitrates enhance clopidogrel response during dual anti-platelet therapy." International Journal of Cardiology 203 (January 2016): 877–81. http://dx.doi.org/10.1016/j.ijcard.2015.11.068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

More sources

Book chapters on the topic "Dual Anti-Platelet Therapy"

1

Bevilacqua, William, and Christopher L. Skelly. "In Patients Who Have Undergone a Lower Extremity Bypass for PAD, Does Dual Anti-platelet Therapy Improve Outcomes?" In Difficult Decisions in Surgery: An Evidence-Based Approach, 491–500. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-33293-2_41.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!